Afabicin
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Afabicin (Debio 1450) is an experimental antibiotic developed by Debiopharm for the treatment of Staphylococcus aureus infections. It is a prodrug which is converted in vivo into the active form afabicin desphosphono (Debio 1452) which acts as an inhibitor of the staphylococcal enoyl-acyl carrier protein reductase (FabI) enzyme.
It has shown similar efficacy in clinical trials to established drugs such as vancomycin, but has not yet been approved for clinical use.
Afabicin (Debio 1450) is an experimental antibiotic developed by Debiopharm for the treatment of Staphylococcus aureus infections. It is a prodrug which is converted in vivo into the active form afabicin desphosphono (Debio 1452) which acts as an inhibitor of the staphylococcal enoyl-acyl carrier protein reductase (FabI) enzyme.
It has shown similar efficacy in clinical trials to established drugs such as vancomycin, but has not yet been approved for clinical use.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1330127328 under CC BY-SA 4.0; modifications have been made.